HomeCompareNATI vs ABBV

NATI vs ABBV: Dividend Comparison 2026

NATI yields 1.87% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $61.6K in total portfolio value
10 years
NATI
NATI
● Live price
1.87%
Share price
$59.99
Annual div
$1.12
5Y div CAGR
33.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,941.70
Full NATI calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NATI vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNATIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NATI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NATI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NATI
Annual income on $10K today (after 15% tax)
$158.69/yr
After 10yr DRIP, annual income (after tax)
$5,050.45/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $16,005.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NATI + ABBV for your $10,000?

NATI: 50%ABBV: 50%
100% ABBV50/50100% NATI
Portfolio after 10yr
$71.5K
Annual income
$15,356.73/yr
Blended yield
21.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NATI
Analyst Ratings
3
Buy
11
Hold
Consensus: Hold
Price Target
$43.33
-27.8% upside vs current
Range: $35.00 — $52.00
Altman Z
5.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NATI buys
0
ABBV buys
0
No recent congressional trades found for NATI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNATIABBV
Forward yield1.87%3.06%
Annual dividend / share$1.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.5%40.6%
Portfolio after 10y$40.8K$102.3K
Annual income after 10y$5,941.70$24,771.77
Total dividends collected$18.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$43.33$256.15

Year-by-year: NATI vs ABBV ($10,000, DRIP)

YearNATI PortfolioNATI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,949$249.24$11,550$430.00$601.00ABBV
2$12,056$340.49$13,472$627.96$1.4KABBV
3$13,368$467.76$15,906$926.08$2.5KABBV
4$14,951$647.11$19,071$1,382.55$4.1KABBV
5$16,900$902.97$23,302$2,095.81$6.4KABBV
6$19,357$1,273.51$29,150$3,237.93$9.8KABBV
7$22,532$1,819.86$37,536$5,121.41$15.0KABBV
8$26,752$2,642.99$50,079$8,338.38$23.3KABBV
9$32,540$3,915.20$69,753$14,065.80$37.2KABBV
10$40,759$5,941.70$102,337$24,771.77$61.6KABBV

NATI vs ABBV: Complete Analysis 2026

NATIStock

National Instruments Corporation provides a software-centric platform and systems to engineers and scientists worldwide. Its programming environments software includes NI LabVIEW, a graphical software platform to visualize hardware configuration, measurement data, and debugging of application; NI LabWindows/CVI, an ANSI C integrated development environment and engineering toolbox; and NI Measurement Studio, a suite of .NET tools for building engineering applications in Microsoft Visual Studio. The company's application software comprises NI TestStand that is used for automated test and measurement applications in manufacturing environment; NI VeriStand, a software environment for configuring real-time testing applications; Flexlogger for sensor configuration and data logging of mixed signals; and NI InsightCM Enterprise, a software for monitoring ancillary rotating equipment. Its operations management and analytic enterprise software include NI DIAdem, which is configuration-based technical data management, analysis, and report generation tools to mine and analyze engineering and measurement data; NI SystemLink, a systems management and data collection software that enables the mass coordination of connected devices, software deployments, and data communications throughout a distributed system; and NI Optimal Plus. The company also offers PXI hardware form factor; and NI semiconductor test systems, as well as software and hardware maintenance, and training and certification services. It serves semiconductor, transportation, aerospace, and defense industries; and government agencies. National Instruments Corporation has strategic agreements with Konrad Technologies, Inc. to develop test systems and solutions for autonomous driving software and hardware validation; and Foretellix Ltd. to enhance the safety of advanced driver-assistance systems and autonomous vehicles. The company was incorporated in 1976 and is headquartered in Austin, Texas.

Full NATI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NATI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NATI vs SCHDNATI vs JEPINATI vs ONATI vs KONATI vs MAINNATI vs JNJNATI vs MRKNATI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.